It is well‐accepted that off‐label drug dosing recommendations for pediatric patients should
be based on the best available evidence. However, the available traditional evidence is …

The paradigm of pediatric drug development has been evolving in a “carrot-and-stick”-based
tactic to address population-specific issues. However, the off-label prescription of adult …

Introduction When pediatric data are not available for a drug, allometric and other methods
are applied to scale drug clearance across the pediatric age-range from adult values. This is …

Robust prediction of pharmacokinetics (PKs) in pediatric subjects of diverse ages,
ethnicities, and morbidities is critical. Qualification of pediatric physiologically‐based …

Rational drug use in special populations is a clinical problem that doctors and pharma-cists
must consider seriously. Neonates are the most physiologically immature and vulnerable to …

Piperine has been reported to inhibit the enzyme activity of cytochrome P450 (CYP) 3A4.
The aim of this study was to develop and validate a physiologically based pharmacokinetic …

Over the last several decades, angiotensin-converting enzyme inhibitors (ACEIs) have been
a staple in the treatment of hypertension and renovascular disorders in children. One of the …

Levetiracetam (Lev) is an antiepileptic drug that has been increasingly used in the epilepsy
pediatric population in recent years, but its pharmacokinetic behavior in pediatric population …

Dosing vancomycin for critically ill neonates is challenging owing to substantial alterations in
pharmacokinetics (PKs) caused by variability in physiology, disease, and clinical …

Nilotinib is a second‐generation BCR‐ABL tyrosine kinase inhibitor for the treatment of
Philadelphia chromosome‐positive chronic myeloid leukemia in both adult and pediatric …